TNFSF11 and atrial fibrillation: In human AF and NP cells, treatment with RANKL, in the presence of proinflammatory stimuli, upregulated the expression of catabolic factors, including proinflammatory cytokines and matrix-degrading enzymes; this result was not seen with treatment with RANKL without proinflammatory stimuli.